Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Less is more: why rare disease funding is on the up

Despite reductions in R&D spending, clinical trials for rare diseases are going full steam ahead. Elly Earls speaks to Alastair Kent of Genetic Alliance UK, Tim Cote of the National Organization for Rare Disorders (NORD) and Dr Steve Groft of the Office of Rare Diseases Research (ORDR) on why drug development should not be affected by the sector's ever-decreasing budget.

Free download worth over $5000
Download our 2018 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global technology, media and telecoms

Go Top